232 related articles for article (PubMed ID: 35492874)
21. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.
Rehman Y; Rosenberg JE
Drug Des Devel Ther; 2012; 6():13-8. PubMed ID: 22291466
[TBL] [Abstract][Full Text] [Related]
22. 3beta-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer.
Evaul K; Li R; Papari-Zareei M; Auchus RJ; Sharifi N
Endocrinology; 2010 Aug; 151(8):3514-20. PubMed ID: 20534728
[TBL] [Abstract][Full Text] [Related]
23. TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer.
Siu MK; Chen WY; Tsai HY; Chen HY; Yin JJ; Chen CL; Tsai YC; Liu YN
Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):172-178. PubMed ID: 28220803
[TBL] [Abstract][Full Text] [Related]
24. Beyond androgen deprivation: ancillary integrative strategies for targeting the androgen receptor addiction of prostate cancer.
McCarty MF; Hejazi J; Rastmanesh R
Integr Cancer Ther; 2014 Sep; 13(5):386-95. PubMed ID: 24867960
[TBL] [Abstract][Full Text] [Related]
25. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.
Stanbrough M; Bubley GJ; Ross K; Golub TR; Rubin MA; Penning TM; Febbo PG; Balk SP
Cancer Res; 2006 Mar; 66(5):2815-25. PubMed ID: 16510604
[TBL] [Abstract][Full Text] [Related]
26. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.
Cai C; Chen S; Ng P; Bubley GJ; Nelson PS; Mostaghel EA; Marck B; Matsumoto AM; Simon NI; Wang H; Chen S; Balk SP
Cancer Res; 2011 Oct; 71(20):6503-13. PubMed ID: 21868758
[TBL] [Abstract][Full Text] [Related]
27. TACC2 is an androgen-responsive cell cycle regulator promoting androgen-mediated and castration-resistant growth of prostate cancer.
Takayama K; Horie-Inoue K; Suzuki T; Urano T; Ikeda K; Fujimura T; Takahashi S; Homma Y; Ouchi Y; Inoue S
Mol Endocrinol; 2012 May; 26(5):748-61. PubMed ID: 22456197
[TBL] [Abstract][Full Text] [Related]
28. Androgen receptor involvement in the progression of prostate cancer.
Suzuki H; Ueda T; Ichikawa T; Ito H
Endocr Relat Cancer; 2003 Jun; 10(2):209-16. PubMed ID: 12790784
[TBL] [Abstract][Full Text] [Related]
29. The androgen receptor can signal through Wnt/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens.
Schweizer L; Rizzo CA; Spires TE; Platero JS; Wu Q; Lin TA; Gottardis MM; Attar RM
BMC Cell Biol; 2008 Jan; 9():4. PubMed ID: 18218096
[TBL] [Abstract][Full Text] [Related]
30. A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer.
Chang KH; Li R; Kuri B; Lotan Y; Roehrborn CG; Liu J; Vessella R; Nelson PS; Kapur P; Guo X; Mirzaei H; Auchus RJ; Sharifi N
Cell; 2013 Aug; 154(5):1074-1084. PubMed ID: 23993097
[TBL] [Abstract][Full Text] [Related]
31. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
32. Androgens and androgen receptor signaling in prostate tumorigenesis.
Zhou Y; Bolton EC; Jones JO
J Mol Endocrinol; 2015 Feb; 54(1):R15-29. PubMed ID: 25351819
[TBL] [Abstract][Full Text] [Related]
33. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
[TBL] [Abstract][Full Text] [Related]
34. Androgen action in the prostate gland.
Yadav N; Heemers HV
Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
[TBL] [Abstract][Full Text] [Related]
35. Androgen hormone action in prostatic carcinogenesis: stromal androgen receptors mediate prostate cancer progression, malignant transformation and metastasis.
Ricke EA; Williams K; Lee YF; Couto S; Wang Y; Hayward SW; Cunha GR; Ricke WA
Carcinogenesis; 2012 Jul; 33(7):1391-8. PubMed ID: 22535887
[TBL] [Abstract][Full Text] [Related]
36. A bypass mechanism of abiraterone-resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling.
Moll JM; Kumagai J; van Royen ME; Teubel WJ; van Soest RJ; French PJ; Homma Y; Jenster G; de Wit R; van Weerden WM
Prostate; 2019 Jun; 79(9):937-948. PubMed ID: 31017696
[TBL] [Abstract][Full Text] [Related]
37. Androgen signal transduction and prostatic carcinoma.
Klocker H; Culig Z; Kaspar F; Hobisch A; Eberle J; Reissigl A; Bartsch G
World J Urol; 1994; 12(2):99-103. PubMed ID: 8087144
[TBL] [Abstract][Full Text] [Related]
38. Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation.
Thelen P; Heinrich E; Bremmer F; Trojan L; Strauss A
Prostate; 2013 Nov; 73(15):1699-709. PubMed ID: 23868789
[TBL] [Abstract][Full Text] [Related]
39. Pomegranate polyphenols down-regulate expression of androgen-synthesizing genes in human prostate cancer cells overexpressing the androgen receptor.
Hong MY; Seeram NP; Heber D
J Nutr Biochem; 2008 Dec; 19(12):848-55. PubMed ID: 18479901
[TBL] [Abstract][Full Text] [Related]
40. The transcriptional programme of the androgen receptor (AR) in prostate cancer.
Lamb AD; Massie CE; Neal DE
BJU Int; 2014 Mar; 113(3):358-66. PubMed ID: 24053777
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
